Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3...
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise. Read More
Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, the companies said...
The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants, and in doing so is seeking to codify tighter...
Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial atlas of specialized immune structures known as tertiary lymphoid structures (TLSs), across...
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner...
Ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, kicking off this weekend, Illumina has announced a new molecular residual disease (MRD)...
The brain is one of the busiest organs in the body, constantly processing and reshaping itself. That activity produces an equally constant stream of molecular byproducts—proteins...
NAIROBI, Kenya — A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus...
Cracked gaskets and rust-like residues trigger FDA warning letter to Alchymars